Published in Gene Therapy Weekly, December 7th, 2000
If the treatment can be applied to humans, it may be used to help slow progression of the disease, which can lead to blindness. Retinitis pigmentosa affects about one in every 4,000 people worldwide.
Optometrists at the University of California, Berkeley, injected subretinally in rats bovine FGF-2 gene via recombinant adeno-associated virus vector (rAAV) with a constitutive cytomegalovirus promoter. The transgenic rats (TgN S334ter-4) were 15 days old.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.